BridgeBio Pharma BBIO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost of license, services, and royalty revenue | $10.3M+134% | $4.4M-51.6% | $9.1M— | —— | —— | |
| License and services revenue | $4.42M+53.4% | $2.88M-65.3% | $8.31M-73.2% | $31M-61.1% | $79.69M+2,717% | |
| Percentage of capitalized property and equipment by Geography | ||||||
| Canada | 54.1%+2.5pp | 51.6%— | —— | —— | —— | |
| U.S. | 41.5%-2.7pp | 44.2%— | —— | —— | —— | |
| Percentage of concentration risk by Geography | ||||||
| APAC | 1.1%— | —— | 2.7%-0.9pp | 3.6%+1.3pp | 2.3%+2.2pp | |
| EMEA | 6%— | —— | 7.7%-24.0pp | 31.7%-34.4pp | 66.1%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BridgeBio Pharma break its business down?
- BridgeBio Pharma (BBIO) reports revenue by product across 2 parts — Cost of license, services, and royalty revenue and License and services revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does BridgeBio Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BridgeBio Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
